| Company Name: | Pfizer, Incorporated | | Ticker Symbol: | PFE | | | WWW Address: | www.pfizer.com | | CEO: | Jeffrey B. Kindler | | No. of Employees: | 81,800 | | Common Issue Type: | CS | | Business Description: | A research-based, global pharmaceutical company which discovers, develops, manufactures and markets prescription medicines for humans and animals.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 18.36 |  0.25 | 18.37 | 18.75 | 18.15 | 18.48 | 18.12 | 58965516 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 148,156.0 | 8,069.5 | 0.71 | 1.20 | 1.28 | 15.2 | 3.5 | 18.48 - 11.62 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 18.36 | $ | | PE Ratio - LTM | 15.2 | |
| Market Capitalisation | 148,156.7 | mil |
| Latest Shares Outstanding | 8,069.5 | mil |
| Earnings pS (EPS) | 1.20 | $ |
| Dividend pS (DPS) | 1.28 | ¢ |
| Dividend Yield | 3.5 | % |
| Dividend Payout Ratio | 107 | % |
| Revenue per Employee | 590,416 | $ |
| Effective Tax Rate | 17.0 | % |
| Float | 6,744.8 | mil |
| Float as % of Shares Outstanding | 99.9 | % |
| Foreign Sales | 27,861 | mil |
| Domestic Sales | 20,435 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 16.10 | % |
| Gross Profit Margin | 89.4 | % |
| EBITDA Margin | 44.6 | % |
| Pre-Tax Profit Margin | 25.0 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | 5.8 | % |
| Return on Equity (ROE) | 12.3 | % |
| Return on Capital Invested (ROCI) | 7.7 | % |
| Current Ratio | 3.1 | |
| Leverage Ratio (Assets/Equity) | 2.1 | |
| Interest Cover | 23.2 | |
| Total Debt/Equity (Gearing Ratio) | 0.70 | |
| LT Debt/Total Capital | 37.0 | % |
| Working Capital pS | 6.17 | $ |
| Cash pS | 0.52 | $ |
| Book-Value pS | 8.19 | $ |
| Tangible Book-Value pS | 3.49 | $ |
| Cash Flow pS | 1.52 | $ |
| Free Cash Flow pS | 1.24 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.24 | |
| Price/Tangible Book Ratio | 5.26 | |
| Price/Cash Flow | 12.0 | |
| Price/Free Cash Flow | 14.8 | |
| P/E as % of Industry Group | 69.0 | % |
| P/E as % of Sector Segment | 90.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 10/22/2009 |
| Dividend Ex-Date | 11/03/2009 |
| Dividend Record Date | 11/05/2009 |
| Dividend Pay Date | 11/30/2009 |
| Dividend Amount | 160 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.64 |
| Current Dividend Yield | 3.5 |
| 5-Y Average Dividend Yield | 4.4 |
| Payout Ratio | 107.0 |
| 5-Y Average Payout Ratio | 71.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 4.4 | 105 | 414,040 | 2,084,904 |
| 4 Weeks | 18.48 | 16.72 | 17.25 | 6.4 | 105 | 486,239 | 9,724,787 |
| 13 Weeks | 18.48 | 15.95 | 16.64 | 10.3 | 104 | 509,917 | 32,634,715 |
| 26 Weeks | 18.48 | 13.94 | 14.96 | 22.7 | 100 | 503,961 | 64,003,015 |
| 52 Weeks | 18.48 | 11.62 | 15.67 | 17.2 | 86 | 552,444 | 138,663,329 |
| YTD | 18.48 | 11.62 | - | 3.7 | 86 | 566,843 | 127,539,633 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 18.11 | 17.84 | 17.09 | 15.87 | 15.27 | 0.71 | 0.73 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -2.27 | 86.7 | -1.63 |
| Income | -3.00 | 3.1 | -18.56 |
| Dividend | 11.44 | 68.1 | 3.51 |
| Capital Spending | -5.04 | NA | -15.91 |
| R&D | 0.59 | NA | -0.23 |
| Normalized Inc. | -1.32 | NA | -4.33 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -6.9 | -2.9 | -0.3 |
| Earnings % | 0.5 | 26.5 | -0.5 |
| EPS % | 0.0 | 26.5 | 2.6 |
| EPS $ | 0.00 | 0.09 | 0.03 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 14.46 |
| Current Ratio | 1.6 |
| Quick Ratio (Acid Test) | 1.2 |
| Liquidity Ratio (Cash) | 0.88 |
| Receivables Turnover | 4.8 |
| Average Collection Period | 75 |
| Working Capital/Equity | 28.0 |
| Working Capital pS | 2.38 |
| Cash-Flow pS | 1.96 |
| Free Cash-Flow pS | 1.01 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.74 |
| Financial Leverage Ratio (Assets/Equity) | 1.9 |
| Debt Ratio | 48.2 |
| Total Debt/Equity (Gearing Ratio) | 0.30 |
| LT Debt/Equity | 0.14 |
| LT Debt/Capital Invested | 40.6 |
| LT Debt/Total Liabilities | 14.9 |
| Interest Cover | 19.7 |
| Interest/Capital Invested | 0.61 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 26.28 |
| Tobin's Q Ratio | 1.33 |
| Current P/E Ratio - LTM | 15.20 |
| Enterprise Value (EV)/EBITDA | 8.85 |
| Enterprise Value (EV)/Free Cash Flow | 25.32 |
| Dividend Yield | 3.5 |
| Price/Tangible Book Ratio - LTM | 5.26 |
| Price/Book Ratio - LTM | 2.24 |
| Price/Cash Flow Ratio | 12.0 |
| Price/Free Cash Flow Ratio - LTM | 14.8 |
| Price/Sales Ratio | 3.23 |
| P/E Ratio (1 month ago) - LTM | 14.8 |
| P/E Ratio (26 weeks ago) - LTM | 12.6 |
| P/E Ratio (52 weeks ago) - LTM | 10.1 |
| 5-Y High P/E Ratio | 26.8 |
| 5-Y Low P/E Ratio | 8.3 |
| 5-Y Average P/E Ratio | 16.7 |
| Current P/E Ratio as % of 5-Y Average P/E | 91 |
| P/E as % of Industry Group | 69.0 |
| P/E as % of Sector Segment | 90.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 11.2 |
| PER SHARE FIGURES |
| LT Debt pS | 1.18 |
| Current Liabilities pS | 4.00 |
| Tangible Book Value pS - LTM | 3.49 |
| Book Value pS - LTM | 8.19 |
| Capital Invested pS | 8.12 |
| Cash pS - LTM | 0.52 |
| Cash Flow pS - LTM | 1.52 |
| Free Cash Flow pS - LTM | 1.24 |
| Earnings pS (EPS) | 1.20 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 14.13 |
| Free Cash Flow Margin 5YEAR AVG | 11.15 |
| Net Profit Margin | 16.8 |
| Net Profit Margin - 5YEAR AVRG. | 22.1 |
| Equity Productivity | 0.84 |
| Return on Equity (ROE) | 14.1 |
| Return on Equity (ROE) - 5YEAR AVRG. | 16.8 |
| Capital Invested Productivity | 0.74 |
| Return on Capital Invested (ROCI) | 12.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 15.2 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | 7.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | 9.5 |
| Gross Profit Margin | 89.4 |
| Gross Profit Margin - 5YEAR AVRG. | 86.9 |
| EBITDA Margin - LTM | 44.6 |
| EBIT Margin - LTM | 26.1 |
| Pre-Tax Profit Margin | 20.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 23.1 |
| Effective Tax Rate | 17.0 |
| Effective Tax Rate - 5YEAR AVRG. | 18.4 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 379 |
| Revenue per Employee | 590,416 |
| Net Income per Employee | 99,071 |
| Average Collection Period | 73 |
| Receivables Turnover | 4.8 |
| Day's Inventory Turnover Ratio | 306 |
| Inventory Turnover | 1.2 |
| Inventory/Sales | 9.1 |
| Accounts Payble/Sales | 3.63 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 3.01 |
| Fixed Assets Turnover | 0.71 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 22.76 |
| Revenue per $ Plant | 3.63 |
| Revenue per $ Common Equity | 0.84 |
| Revenue per $ Capital Invested | 0.74 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 30.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 32.0 |
| Research & Devlopment (R&D) as % of Revenue | 16.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 16.5 |
|
|  
| | |  |  | |
| |